Veterinary Cooperative Oncology Group—Common Terminology Criteria for Adverse Events (VCOG‐CTCAE v2) following investigational therapy in dogs and cats

• DOI: 10.1111/vco.12677
• Publication Date: 2021-01-15T05:26:03Z
• Authors: Amy K. LeBlanc; Matthew Atherton; R. Timothy Bentley; C. Elizabeth Boud...; Jenna H. Burton; Kaitlin M. Curran; Steven Dow; Michelle A. Giuff...; Heidi B. Kellihan; Nicola J. Mason; Michelle Oblak; Laura E. Selmic; Kimberly A. Selting; Ameet Singh; Sonja Tjostheim; David M. Vail; Kristen M. Weishaar; Erika P. Berger; John H. Rossmeisl; Christina Mazcko
• Keywords: Grading (engineering)

The updated VCOG-CTCAE v2 guidelines contain several important updates and additions since the last update (v1.1) was released in 2011 published within Veterinary Comparative Oncology 2016. As Cooperative Group (VCOG) is no longer an active entity, original authors contributors to v1.0 v1.1 were consulted for input, additional co-authors sought expansion refinement of adverse event (AE) categories. includes expanded neurology, cardiac immunologic AE sections, addition procedural-specific AEs. It our intent that, through inclusion from ACVIM subspecialties American College Surgery, that we can more comprehensively capture AEs are observed during clinical studies conducted across a variety disease states, scenarios, body systems. also these veterinary CTCAE will offer improved application ease use practice general, as well trials assess new therapeutic strategies animals with diseases. Throughout revision process, strived ensure grading structure each category reflective decision-making process applied determination dose-limiting events. phase I trial decisions based on criteria ultimately determine maximally tolerated dose, there impact standard dosing recommendations any drug registration or application. This document should be regularly reflect ongoing carried out patients.